Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET

Company Participants

Cristi Barnett - Corporate Communications & Investor Relations

Gilmore O’Neill - Chief Executive Officer

Baisong Mei - Chief Medical Officer

Erick Lucera - Chief Financial Officer

Conference Call Participants

Terence Flynn - Morgan Stanley

Samantha Semenkow - Citi

Greg Harrison - Bank of America

Joon Lee - Truist Securities

Gena Wang - Barclays

Dae Gon Ha - Stifel

Yanan Zhu - Wells Fargo

Rick Bienkowski - Cantor Fitzgerald

Rich Law - Credit Suisse

Jack Allen - Baird

Jay Olson - Oppenheimer

Luca Issi - RBC Capital Markets

Liisa Bayko - Evercore ISI

Brian Cheng - J.P. Morgan

Operator

Good morning and welcome to Editas Medicine's Second Quarter Conference Call. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.

Cristi Barnett

Thank you, Maria. Good morning, everyone and welcome to our second quarter 2023 conference call. Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available in the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A.

As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K which is on file with the SEC as updated by our subsequent filings. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change.

Now, I will turn the call over to our CEO, Gilmore O’Neill.

Gilmore O’Neill

Thanks, Christie and good morning, everyone. Thank you for joining us today for Editas' second quarter earnings call. I am joined today by 3 other members of the Editas executive team, our Chief Medical Officer, Baisong Mei; our new Chief Financial Officer, Erick Lucera; and our new Chief Scientific Officer, Linda Burkly [ph]. I joined Editas 1 year ago tasked with guiding its evolution from platform development company to commercial therapeutics company.